Lymphoma Hub (@lymphomahub) 's Twitter Profile
Lymphoma Hub

@lymphomahub

A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia. linktr.ee/LymphomaHub_ #lymsm

ID: 1582593798

linkhttp://www.lymphomahub.com calendar_today10-07-2013 08:56:22

10,10K Tweet

10,10K Followers

2,2K Following

Lymphoma Hub (@lymphomahub) 's Twitter Profile Photo
Lymphoma Hub
@lymphomahub

2 months ago

🚨 NEWS 🚨 The U.S. FDA has approved the tablet formulation of zanubrutinib for all five approved indications, including CLL/SLL, WM, MCL (after failure of ≥1 LOT), MZL (after failure of ≥1 anti-CD20-based regimen), and FL after failure of ≥2 LOT. Read more here:

🚨 NEWS 🚨 The <a href="/US_FDA/">U.S. FDA</a> has approved the tablet formulation of zanubrutinib for all five approved indications, including CLL/SLL, WM, MCL (after failure of ≥1 LOT), MZL (after failure of ≥1 anti-CD20-based regimen), and FL after failure of ≥2 LOT. Read more here: